Chemopreventive compounds-View from the other side

Chemico-Biological Interactions

Volumn 180, Issue 1, 2009, Pages 1-9

  Hodek, P ^a   Krizkova J ^a   Burdova K ^a   Sulc M ^a   Kizek, R ^b   Hudecek J ^a   Stiborova M ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

^b MENDEL UNIVERSITY IN BRNO   (Czech Republic)

Author keywords

Cancer prevention; Cytochrome P450; Drug interactions; Flavonoids; Phytochemicals; Xenobiotics

Indexed keywords

3 INDOLEMETHANOL; ALPHA NAPHTHOFLAVONE; ALPHA TOCOPHEROL; ANTINEOPLASTIC AGENT; ASCORBIC ACID; BETA CAROTENE; CYTOCHROME P450; DEXAMETHASONE; FLAVONOID; FOOD ADDITIVE; NARINGENIN; NATURAL PRODUCT; PLANT MEDICINAL PRODUCT; QUERCETIN; RETINOL; RIFAMPICIN; SULFORAPHANE; TAMOXIFEN; TERFENADINE; XENOBIOTIC AGENT;

ANTINEOPLASTIC ACTIVITY; BIOTRANSFORMATION; BREAST CANCER; CANCER PREVENTION; CANCER RISK; CHEMOPROPHYLAXIS; CLINICAL TRIAL; COLORECTAL ADENOMA; COMPETITIVE INHIBITION; CONCENTRATION RESPONSE; DEEP VEIN THROMBOSIS; DIET SUPPLEMENTATION; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG FATALITY; DRUG METABOLISM; DRUG TREATMENT FAILURE; ENDOMETRIUM CANCER; FOOD DRUG INTERACTION; GRAPEFRUIT JUICE; HERB DRUG INTERACTION; HUMAN; IN VITRO STUDY; LUNG CANCER; LUNG EMBOLISM; METABOLISM; MOLECULAR INTERACTION; NONHUMAN; RECURRENT CANCER; REVIEW; STROKE;

ANTICARCINOGENIC AGENTS; CYTOCHROME P-450 ENZYME SYSTEM; HUMANS; NEOPLASMS; RISK FACTORS; XENOBIOTICS;

EID: 67349092476     PISSN: 00092797     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cbi.2009.01.003     Document Type: Review

References (88)

1. Phillips D.H. DNA adducts as markers of exposure and risk. Mutat. Res. 577 (2005) 284-292
2. Doll R., and Peto R. The causes of cancer: quantitative estimates of avoidable risks of cancer in the United States today. J. Natl. Cancer Inst. 66 (1981) 1191-1208
3. Lichtenstein P., Holm N.V., Verkasalo P.K., Iliadou A., Kaprio J., Koskenvuo M., Pukkala E., Skytthe A., and Hemminki K. Environmental and heritable factors in the causation of cancer-analyses of cohorts of twins from Sweden, Denmark, and Finland. N. Engl. J. Med. 343 (2000) 78-85
4. Trock B., Lanza E., and Greenwald P. Dietary fiber, vegetables, and colon cancer: critical review and meta-analyses of the epidemiologic evidence. J. Natl. Cancer. Inst. 82 (1990) 650-661
5. Tsuda H., Ohshima Y., Nomoto H., Fujita K., Matsuda E., Iigo M., Takasuka N., and Moore M.A. Cancer prevention by natural compounds. Drug Metab. Pharmacokinet. 19 (2004) 245-263
6. Gopalakrishnan A., and Tony Kong A.N. Anticarcinogenesis by dietary phytochemicals: Cytoprotection by Nrf2 in normal cells and cytotoxicity by modulation of transcription factors NF-κB and AP-1 in abnormal cancer cells. Food Chem. Toxicol. 46 (2008) 1257-1270
7. Bhat T.A., and Singh R.P. Tumor angiogenesis-a potential target in cancer chemoprevention. Food Chem. Toxicol. 46 (2008) 1334-1345
8. Steinmetz K.A., and Potter J.A. Vegetables, fruit, and cancer prevention: a review. J. Am. Diet. Assoc. 96 (1996) 1027-1039
9. Skibola C.F., and Smith M.T. Potential health impacts of excessive flavonoid intake. Free Radic. Biol. Med. 29 (2000) 375-383
10. Fisher B., Costantino J.P., Wickerham D.L., Redmond C.K., Kavah M., Cronin W.M., Vogel V., Rodiboux A., et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J. Natl. Cancer Inst. 90 (1998) 1371-1388
11. Bao T., Prowell T., and Stearns V. Chemoprevention of breast cancer: tamoxifen, raloxifene, and beyond. Am. J. Ther. 13 (2006) 337-348
12. Omenn G.S., Goodman G.E., Thornquist M.D., Balmes J., Cullen M.R., Glass A., Keogh J.P., Meyskens F.L., Valanis B., Williams J.H., Barnhart S., and Hammar S. Effects of a combination of β-carotene and vitamin A on lung cancer and cardiovascular disease. N. Engl. J. Med. 334 (1996) 1150-1155
13. The ATBC Study Group. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. The alpha-tocopherol beta carotene cancer prevention study group. N. Engl. J. Med. 330 (1994) 1029-1035
14. Baron J.A., Cole B.F., Mott L., Haile R., Grau M., Church T.R., Beck G.J., and Greenberg E.R. Neoplastic and antineoplastic effects of β-carotene on colorectal adenoma recurrence: results of a randomized trial. J. Natl. Cancer Inst. 95 (2003) 717-722
15. Mayne S.T., Handelman G.J., and Beecher G. β-Carotene and lung cancer promotion in heavy smokers-a plausible relationship?. J. Natl. Cancer Inst. 88 (1996) 1513-1515
16. Steinkellner H., Rabot S., Freywald C., Nobis E., Scharf G., Chabicovsky M., Knasmüller S., and Kassie F. Effects of cruciferous vegetables and their constituents on drug metabolizing enzymes involved in the bioactivation of DNA-reactive dietary carcinogens. Mutat. Res. 480 (2001) 285-297
17. Higdon J.V., Delage B., Williams D.E., and Dashwood R.H. Cruciferous vegetables and human cancer risk: epidemiologic evidence and mechanistic basis. Pharmacol. Res. 55 (2007) 224-236
18. Voorrips L.E., Goldbohm R.A., van Poppel G., Sturmans F., Hermus R.J., and Brandt v.d.P.A. Vegetable and fruit consumption and risks of colon and rectal cancer in a prospective cohort study: The Netherlands Cohort Study on Diet and Cancer. Am. J. Epidemiol. 152 (2000) 1081-1092
19. Conney A.H. Enzyme induction and dietary chemicals as approaches to cancer chemoprevention: the seventh DeWitt S. Goodman lecture. Cancer Res. 63 (2003) 7005-7031
20. Hodek P., Trefil P., and Stiborová M. Flavonoids-potent and versatile biologically active compounds interacting with cytochromes P450. Chem.-Biol. Interact. 139 (2002) 1-21
21. Galati G., and O'Brien P.J. Potential toxicity of flavonoids and other dietary phenolics: significance for their chemopreventive and anticancer properties. Free Rad. Biol. Med. 37 (2004) 287-303
22. Min K., and Ebele S.E. Flavonoid effects on DNA oxidation at low concentrations relevant to physiological levels. Food Chem. Toxicol. 46 (2008) 96-104
23. Walle T., Vincent T.S., and Walle U.K. Evidence of covalent binding of the dietary flavonoid quercetin to DNA and protein in human intestinal and hepatic cells. Biochem. Pharmacol. 65 (2003) 1603-1610
24. Sergediene E., Jonsson K., Szymusiak H., Tyrakowska B., Rietjens I.M.C.M., and Cenas N. Prooxidant toxicity of polyphenolic antioxidants to HL-60 cells: description of quantitative structure-activity relationships. FEBS Lett. 462 (1999) 392-396
25. Matsuo M., Sasaki N., Saga K., and Kaneko T. Cytotoxicity of flavonoids toward cultured normal human cells. Biol. Pharm. Bull. 28 (2005) 253-259
26. You L., Sar M., Bartolucci E.J., McIntyre B.S., and Sriperumbudur R. Modulation of mammary gland development in prepubertal male rats exposed to genistein and methoxychlor. Toxicol. Sci. 66 (2002) 216-225
27. Halliwell B. Dietary polyphenols: good, bad, or indifferent for your health?. Cardiovasc. Res. 73 (2007) 341-347
28. Josephy P.D., Guengerich F.P., and Miners J.O. Phase I" and "phase II" drug metabolism: terminology that we should phase out?. Drug Metab. Rev. 37 (2005) 575-580
29. Hollman P.C., and Katan M.B. Absorption, metabolism and health effects of dietary flavonoids in man. Biomed. Pharmacother. 51 (1997) 305-310
30. Kroon P.A., Clifford M.N., Crozier A., Day A.J., Donovan J.L., Manach C., and Williamson G. How should we assess the effects of exposure to dietary polyphenols in vitro?. Am. J. Clin. Nutr. 80 (2004) 15-21
31. Evans W.E., and Relling M.V. Pharmacogenomics: translating functional genomics into rational therapeutics. Science 286 (1999) 487-491
32. Nebert D.W., and Dalton T.P. The role of cytochrome P450 enzymes in endogenous signalling pathways and environmental carcinogenesis. Nat. Rev. Cancer 6 (2006) 947-960
33. Waxman D.J. P450 gene induction by structurally diverse xenochemicals: central role of nuclear receptors CAR, PXR, and PPAR. Arch. Biochem. Biophys. 369 (1999) 11-23
34. Monostory K., and Pascussi J.M. Regulation of drug-metabolizing human cytochrome P450s. Acta Chim. Slov. 55 (2008) 20-37
35. Xu C., Li C.Y., and Kong A.T. Induction of phase I, II and III drug metabolism/transport by xenobiotics. Arch. Pharm. Res. 28 (2005) 249-268
36. Gurtoo H.L., Koser P.L., Bansal S.K., Fox H.W., Sharma S.D., Mulhern A.I., and Pavelic Z.P. Inhibition of aflatoxin B1-hepatocarcinogenesis in rats by β-naphthoflavone. Carcinogenesis 6 (1985) 675-678
37. Snyderwine E.G., Nouso K., and Schut H.A. Effect of 3-methylcholanthrene induction on the distribution and DNA adduction of 2-amino-3-methylimidazo[4,5-f]quinoline (IQ) in F344 rats. Food Chem. Toxicol. 31 (1993) 415-423
38. Wislocki P.G., Miller E.C., Miller J.A., McCoy E.C., and Rosenkranz H.S. Carcinogenic and mutagenic activities of safrole, 1′-hydroxysafrole, and some known or possible metabolites. Cancer Res. 37 (1977) 1883-1891
39. Sivaraman L., Leatham M.P., Yee J., Wilkens L.R., Lau A.F., and Le Marchand L. CYP1A1 genetic polymorphisms and in situ colorectal cancer. Cancer Res. 54 (1994) 3692-3695
40. Wogan G.N., Hecht S.S., Felton J.S., Conney A.H., and Loeb L.A. Environmental and chemical carcinogenesis. Semin. Cancer Biol. 14 (2004) 473-486
41. Guengerich F.P. Cytochrome P450 and chemical toxicology. Chem. Res. Toxicol. 21 (2008) 70-83
42. Schwarz D., and Roots I. In vitro assessment of inhibition by natural polyphenols of metabolic activation of procarcinogens by human CYP1A1. Biochem. Biophys. Res. Commun. 303 (2003) 902-907
43. Huang M.T., Wood A.W., Chang R.L., Yagi H., Sayer J.M., Jerina D.M., and Conney A.H. Inhibitory effect of 3-hydroxybenzo[a]pyrene on the mutagenicity and tumorigenicity of (±)-7β,8α-dihydroxy-9α,10α-epoxy-7,8,9,10-tertahydrobenzo[a]pyrene. Cancer Res. 46 (1986) 558-566
44. Uno S., Dalton T.P., Shertzer H.G., Genter M.B., Warshawsky D., Talaska G., and Nebert D.W. Benzo[a]pyrene-induced toxicity: paradoxical protection in Cyp1a1(-/-) knockout mice having increased hepatic BaP-DNA adduct levels. Biochem. Biophys. Res. Commun. 289 (2001) 1049-1056
45. Arlt V.M., Stiborová M., Henderson C.J., Thiemann M., Frei E., Aimová D., Singhs R., da Costa G.G., Schmitz O.J., Farmer P.B., Wolf C.R., and Phillips D.H. Metabolic activation of benzo[a]pyrene in vitro by hepatic cytochrome P450 contrasts with detoxification in vivo: experiments with hepatic cytochrome P450 reductase null mice. Carcinogenesis 29 (2008) 656-665
46. Tsyrlov I.B., Mikhailenko V.M., and Gelboin H.V. Isozyme- and species-specific susceptibility of cDNA-expressed CYP1A P-450s to different flavonoids. Biochim. Biophys. Acta 1205 (1994) 325-335
47. Bořek-Dohalská L., Hodek P., Šulc M., and Stiborová M. α-Naphthoflavone acts as activator and reversible or irreversible inhibitor of rabbit microsomal CYP3A6. Chem.-Biol. Interact. 138 (2001) 85-106
48. Ueng Y.-F., Kuwabara T., Chun Y.-J., and Guengerich F.P. Cooperativity in oxidations catalyzed by cytochrome P450 3A4. Biochemistry 36 (1997) 370-381
49. Kang I.H., Kim H.J., Oh H., Park Y.I., and Dong M.S. Biphasic effects of the flavonoids quercetin and naringenin on the metabolic activation of 2-amino-3,5-dimethylimidazo[4,5-f]quinoline by Salmonella typhimurium TA1538 co-expressing human cytochrome P450 1A2, NADPH-cytochrome P450 reductase, and cytochrome b5. Mutat. Res. 545 (2004) 37-47
50. Schwab G.E., Raucy J.L., and Johnson E.F. Modulation of rabbit and human hepatic cytochrome P450 catalyzed steroid hydroxylation by α-naphthoflavone. Mol. Pharmacol. 33 (1998) 493-499
51. Bailey D.G., Malcolm J., Arnold O., and Spence J.D. Grapefruit juice-drug interactions. Br. J. Clin. Pharmacol. 46 (1998) 101-110
52. Tang W., and Stearns R.A. Heterotropic cooperativity of cytochrome P450 3A4 and potential drug-drug interactions. Curr. Drug Metab. 2 (2001) 185-198
53. Izzo A.A., and Ernst E. Interactions between herbal medicines and prescribed drugs: a systematic review. Drugs 61 (2001) 2163-2175
54. Lambert J.D., Sang S., Lu A.Y., and Yang C.S. Metabolism of dietary polyphenols and possible interactions with drugs. Curr. Drug Metab. 8 (2007) 499-507
55. Spence J.D. Drug interactions with grapefuit: whose responsibility is to warn the public?. Clin. Pharmacol. Ther. 61 (1997) 395-400
56. Kaminsky L.S., and Zhang Q. The small intestine as a xenobiotic-metabolizing organ. Drug Metab. Disp. 31 (2003) 1520-1525
57. Galetin A., and Houston J.B. Intestinal and hepatic metabolic activity of five cytochrome P450 enzymes: impact on prediction of first-pass metabolism. J. Pharmacol. Exp. Ther. 318 (2006) 1220-1229
58. Lim C.C., Ferguson L.R., and Tannock G.W. Dietary fibres as "prebiotics": implications for colorectal cancer. Mol. Nutr. Food Res. 49 (2005) 609-619
59. Sergent T., Ribonnet L., Kolosova A., Garsou S., Schaut A., De Saeger S., Van Peteghem C., Larondelle Y., Pussemier L., and Schneider Y.J. Molecular and cellular effects of food contaminants and secondary plant components and their plausible interactions at the intestinal level. Food Chem. Toxicol. 46 (2008) 813-841
60. Paine M.F., Hart H.L., Ludington S.S., Haining R.L., Rettie A.E., and Zeldin D.C. The human intestinal cytochrome P450 "pie". Drug Metab. Dispos. 34 (2006) 880-886
61. Murray M. Altered CYP expression and function in response to dietary factors: potential roles in disease pathogenesis. Curr. Drug Metab. 7 (2006) 67-81
62. Emoto C., Yamazaki H., Yamasaki S., Shimada N., Nakajima M., and Yokoi T. Use of everted sacs of mouse small intestine as enzyme sources for the study of drug oxidation activities in vitro. Xenobiotica 30 (2000) 971-982
63. Mori Y., Tatematsu K., Koide A., Sugie S., Tanaka T., and Mori H. Modification by curcumin of mutagenic activation of carcinogenic N-nitrosamines by extrahepatic cytochromes P-450 2B1 and 2E1 in rats. Cancer Sci. 97 (2006) 896-904
64. Van Lieshout E.M., Bedaf M.M., Pieter M., Ekkel C., Nijhoff W.A., and Peters W.H. Effects of dietary anticarcinogens on rat gastrointestinal glutathione S-transferase theta 1-1 levels. Carcinogenesis 19 (1998) 2055-2057
65. Yamazoe Y., Nagata K., Yoshinari K., Fujita K., Shiraga T., and Iwasaki K. Sulfotransferase catalyzing sulfation of heterocyclic amines. Cancer Lett. 143 (1999) 103-107
66. Kadlubar F.F. Biochemical individuality and its implications for drug and carcinogen metabolism: recent insights from acetyltransferase and cytochrome P4501A2 phenotyping and genotyping in humans. Drug Metab. Rev. 26 (1994) 37-46
67. Sugimura T., and Wakabayashi K. Heterocyclic amines: new mutagens and carcinogens in cooked foods. Adv. Exp. Med. Biol. 283 (1991) 569-578
68. Turesky R.J., Lang N.P., Butler M.A., Teitel C.H., and Kadlubar F.F. Metabolic activation of carcinogenic heterocyclic aromatic amines by human liver and colon. Carcinogenesis 12 (1991) 1839-1845
69. MacGregor J.T., and Jurd L. Mutagenicity of plant flavonoids: structural requirements for mutagenic activity in Salmonella typhimurium. Mutat. Res. 54 (1978) 297-309
70. Rahman A., Shahabuddin S., Hadi S.M., Parish J.H., and Ainley K. Strand scission in DNA induced by quercetin and Cu(II): role of Cu(I) and oxygen free radicals. Carcinogenesis 10 (1989) 1833-1839
71. Omiecinski C.J., Remmel R.P., and Hosagrahara V.P. Concise review of the cytochrome P450s and their roles in toxicology. Toxicol. Sci. 48 (1999) 151-156
72. Gradelet S., Le Bon A.M., Berges R., Suschetet M., and Astorg P. Dietary carotenoids inhibit aflatoxin B1-induced liver preneoplastic foci and DNA damage in the rat: role of the modulation of aflatoxin B1 metabolism. Carcinogenesis 19 (1998) 403-411
73. Jang E.H., Park Y.C., and Chung W.G. Effect of dietary supplements on induction and inhibition of cytochrome P450s protein expression in rats. Food Chem. Toxicol. 42 (2004) 1749-1756
74. Gooderham N.J., Creton S., Lauber S.N., and Zhu H. Mechanisms of action of the carcinogenic heterocyclic amine PhIP. Toxicol. Lett. 168 (2007) 269-277
75. Crofts F.G., Sutter T.R., and Strickland P.T. Metabolism of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine by human cytochrome P4501A1, P4501A2 and P4501B1. Carcinogenesis 19 (1998) 1969-1973
76. Smith C.M., Graham R.A., Krol W.L., Silver I.S., Negishi M., Wang H., and Lecluyse E.L. Differential UGT1A1 induction by chrysin in primary human hepatocytes and HepG2 cells. J. Pharmacol. Exp. Ther. 315 (2005) 1256-1264
77. Yueh M.F., Kawahara M., and Raucy J. Cell-based high-throughput bioassays to assess induction and inhibition of CYP1A enzymes. Toxicol. In Vitro 19 (2005) 275-287
78. Zhang Z.Y., Pelletier R.D., Wong Y.N., Sugawara M., Zhao N., and Littlefi{ligature}eld B.A. Preferential inducibility of CYP1A1 and CYP1A2 by TCDD: Differential regulation in primary human hepatocytes versus transformed human cells. Biochem. Biophys. Res. Comm. 341 (2006) 399-407
79. Martignoni M., de Kanter R., Grossi P., Mahnke A., Saturno G., and Monshouwer M. An in vivo and in vitro comparison of CYP induction in rat liver and intestine using slices and quantitative RT-PCR. Chem.-Biol. Interact. 151 (2004) 1-11
80. Ferguson L.R. Role of plant polyphenols in genomic stability. Mutat. Res. 475 (2001) 89-111
81. Xu M., Schut H.A.J., Bjeldanes L.F., Williams D.E., Bailey G.S., and Dashwood R.H. Inhibition of 2-amino-3-methylimidazo[4,5-f]quinoline-DNA adducts by indole-3-carbinol: dose-response studies in the rat colon. Carcinogenesis 18 (1997) 2149-2153
82. Lin J.H., Chiba M., and Baillie T.A. Is the role of the small intestine in first-pass metabolism overemphasized?. Pharmacol. Rev. 51 (1999) 135-158
83. Wang X.D., and Morris M.E. Pharmacokinetics and bioavailability of the flavonoid 7,8-benzoflavone in rats. J. Pharm. Sci. 97 (2008) 4546-4556
84. Ciolino H.P., Daschner P.J., and Yeh G.C. Dietary flavonols quercetin and kaempferol are ligands of the aryl hydrocarbon receptor that affect CYP1A1 transcription differentially. Biochem. J. 340 (1999) 715-722
85. Zhang Q.Y., Wikoff J., Dunbar D., Fasco M., and Kaminsky L. Regulation of cytochrome P4501A1 expression in rat small intestine. Drug Metab. Dispos. 25 (1997) 21-26
86. Sugiyama T., Kubota Y., Shinozuka K., Yamada S., Yamada K., and Umegaki K. Induction and recovery of hepatic drug metabolizing enzymes in rats treated with Ginkgo biloba extract. Food Chem. Toxicol. 42 (2004) 953-957
87. McClain R.M., Wolz E., Davidovich A., Edwards J., and Bausch J. Reproductive safety studies with genistein in rats. Food Chem. Toxicol. 45 (2007) 1319-1332
88. Stiborová M., Rupertová M., Hodek P., Frei E., and Schmeiser H.H. Monitoring of DNA adducts in humans and P-32-postlabelling methods. A review. Collect. Czech. Chem. Commun. 69 (2004) 476-498